Virus News and Research

Latest Virus News and Research

Researchers develop influenza virus-like particle-based hybrid vaccine for both influenza and SARS-CoV-2 viruses

In a new study, a team of researchers developed a hybrid vaccine for SARS-CoV-2 and influenza viruses using influenza virus-like particles (VLP).

4 Feb 2022

Researchers suggest that visible blue light is a safe and variant-agnostic therapy against SARS-CoV-2

In a new study, researchers showed that 425 nm blue light can inactivate all major SARS CoV 2 variants.

4 Feb 2022

Molecular simulations provide insight into SARS-CoV-2 variant RBD interactions with ACE2 and mAbs

Researchers aimed to understand the relationship between the SARS-CoV-2 receptor-binding domain and both human receptors and therapeutic targets.

3 Feb 2022

Evaluating effects of D614G and P681R/H mutations on SARS-CoV-2 VOCs

Researchers evaluate how the D614G and P681H mutations alter the attributes of SARS-CoV-2 VOCs.

3 Feb 2022

SARS-CoV-2 human challenge study offers novel insights into viral kinetics

Researchers discuss the results of a human challenge study to provide novel insights into the early dynamics of SARS-CoV-2 infection.

3 Feb 2022

Smartphone system sends COVID-19 exposure alerts to users in Missouri

Smartphones can help alert you if you've been exposed to someone with COVID-19. Washington University in St. Louis is expanding access to MO/Notify, a smartphone system that privately sends pop-up alerts to users in Missouri when they have spent time near someone who later tests positive for COVID-19.

3 Feb 2022

Global efforts to track COVID-19 variants grossly underreported a probable variant of concern in Nigeria

If the United States ignores COVID-19 in Nigeria, we forgo global genomic surveillance at our own peril, reports a new Northwestern Medicine study published in Nature Communications.

3 Feb 2022

Innate and adaptive immune responses to SARS-CoV-2 in convalescent children and adults

In a new study, researchers explored the systemic immune responses during the acute and convalescent phases of SARS-CoV-2 in children and adults with the same disease severity.

3 Feb 2022

Exploring human milk oligosaccharides as a method of COVID-19 prevention

New research was conducted to ascertain whether antiviral and immunomodulatory activities of human milk oligosaccharides can be efficacious in the prevention and treatment against COVID-19.

3 Feb 2022

Study finds no strong evidence to suggest vaccination improves symptoms of post-acute COVID-19 syndrome

In this study, researchers found no evidence of a strong effect of SARS-CoV-2 vaccination on the symptoms associated with PACS over time.

3 Feb 2022

Neutralizing antibodies against SARS-CoV-2 variants induced by homologous and heterologous COVID-19 booster vaccination

In this study, scientists focused on identifying tentative cut-offs for large-scale evaluations of immune protection against SARS-CoV-2 and its variants.

3 Feb 2022

Study describes the first three days of SARS-CoV-2 infection in an ALI model of proximal airway epithelium

Researchers evaluated the initial three days of SARS-CoV-2 infection via scRNAseq dataset in humanized in vitro model.

3 Feb 2022

A relative COVID-19 survival analysis

Researchers from the University of California Riverside, Texas A & M University, Washington University, and the Medical College of Georgia have been investigating the risks of death by age due to COVID-19 infection compared to deaths by other causes in Hubei province, China.

3 Feb 2022

Red foxes susceptible to SARS-CoV-2 infection

Working towards the aim to determine the SARS-CoV-2 susceptibility of common wildlife species, the researchers in the United States have found that red fox (Vulpes vulpes) can experimentally become infected with SARS-CoV-2 and can shed virus in its oral and nasal secretions.

3 Feb 2022

Study results strongly support COVID mRNA vaccine boosters for nursing home residents

Researchers evaluate the vaccine effectiveness of mRNA booster dose in nursing home residents who completed the primary series of mRNA vaccination.

2 Feb 2022

Nanoparticle vaccine effective against eight SARS-CoV-2 variants in non-human primates

Researchers demonstrate that SARS-CoV-2 RBD-based nanoparticle vaccine induces neutralizing antibodies against SARS-CoV-2 variants.

2 Feb 2022

Antigenic map of SARS-CoV-2 variants reveals amino acid substitutions that govern immune escape and immunodominance

Researchers use antigenic cartography to analyze cross-reactivity patterns of eight groups of human sera on a panel of SARS-CoV-2 variants.

2 Feb 2022

Omicron variant's 'milder' outcomes may be due to more population immunity

The SARS-CoV-2 Omicron variant's "milder" outcomes are likely due to more population immunity compared to earlier waves of the pandemic rather than the virus's properties, according to a paper by William Hanage, associate professor of epidemiology and co-director of the Center for Communicable Disease Dynamics at Harvard T.H. Chan School of Public Health, and Roby Bhattacharyya, assistant professor at Massachusetts General Hospital and Harvard Medical School and associate member at the Broad Institute of MIT and Harvard.

2 Feb 2022

Booster dose of Covaxin vaccine candidate neutralizes Omicron and Delta variants

Researchers evaluate the neutralization potential of sera samples from subjects boosted with the Covaxin against the SARS-CoV-2 Omicron variant.

2 Feb 2022

UK's world-leading human challenge study provides new insights into mild SARS-CoV-2 infections

Findings from the UK's world-leading human challenge study provide new insights into mild infections with SARS-CoV-2 in healthy young adults.

2 Feb 2022

Virus News and Research

Latest Virus News and Research

Researchers develop influenza virus-like particle-based hybrid vaccine for both influenza and SARS-CoV-2 viruses

Researchers suggest that visible blue light is a safe and variant-agnostic therapy against SARS-CoV-2

Molecular simulations provide insight into SARS-CoV-2 variant RBD interactions with ACE2 and mAbs

Evaluating effects of D614G and P681R/H mutations on SARS-CoV-2 VOCs

SARS-CoV-2 human challenge study offers novel insights into viral kinetics

Smartphone system sends COVID-19 exposure alerts to users in Missouri

Global efforts to track COVID-19 variants grossly underreported a probable variant of concern in Nigeria

Innate and adaptive immune responses to SARS-CoV-2 in convalescent children and adults

Exploring human milk oligosaccharides as a method of COVID-19 prevention

Study finds no strong evidence to suggest vaccination improves symptoms of post-acute COVID-19 syndrome

Neutralizing antibodies against SARS-CoV-2 variants induced by homologous and heterologous COVID-19 booster vaccination

Study describes the first three days of SARS-CoV-2 infection in an ALI model of proximal airway epithelium

A relative COVID-19 survival analysis

Red foxes susceptible to SARS-CoV-2 infection

Study results strongly support COVID mRNA vaccine boosters for nursing home residents

Nanoparticle vaccine effective against eight SARS-CoV-2 variants in non-human primates

Antigenic map of SARS-CoV-2 variants reveals amino acid substitutions that govern immune escape and immunodominance

Omicron variant's 'milder' outcomes may be due to more population immunity

Booster dose of Covaxin vaccine candidate neutralizes Omicron and Delta variants

UK's world-leading human challenge study provides new insights into mild SARS-CoV-2 infections

A new way of characterising biomolecules eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Newsletters you may be interested in